Clinical significance of Serum cystatin C in monitoring early renal damage of lung cancer patients with chemotherapy

OBJECTIVE: To evaluate the levels of serum cystatin C (Cys C) and discuss its role and status in renal function of patients with lung cancer chemotherapy. METHODS: Serum Cys C and creatinine(CREA) were tested and compared before and after chemotherapy in lung cancer patients (n=96) and healthy people (n=92). At the same time, serum creatinine (Scr) and 24 h urine creatinine (Ucr) level were detected and creatinine clearance rate (Ccr) was compared. RESULTS: The average CysC before and after the first course of treatment for cancer patients were (1.20±0.37) mg/L and (1.78±0.56) mg/L, respectively; while the average for heathy people was (0.82±0.13) mg/L. The serum Cys C, Scr and Ccr level had significant differences in lung cancer patients before and after chemotherapy (one cycle)(P values were respectivly 0.01, 0.03, 0.04). After chemotherapy, the abnormal detection rate of serum Cys C was significantly higher than Scr and Ccr abnormal detection rate (36.5%, 15.6% and 16.7%), and the difference was statistically significant (P=0.03).CONCLUSION: Cys C has clinical refernce value in reflecting early kidney function damage for lung cancer patients after chemotherapy.